Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

GHRP-2 Overview, Dosing & Safety | Peptide Database

GHRP-2 (Pralmorelin) Growth Hormone Releasing Peptide-2 | Pralmorelin Community Research Join others researching GHRP-2 — share findings, ask questions, and learn from real experiences GHRP-2 is a synthetic growth hormone secretagogue that stimulates the pitui

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

GHRP-2 (Pralmorelin)

Growth Hormone Releasing Peptide-2 | Pralmorelin

Community Research

Join others researching GHRP-2 — share findings, ask questions, and learn from real experiences

GHRP-2 is a synthetic growth hormone secretagogue that stimulates the pituitary gland to release growth hormone. It is one of the most potent members of the GHRP family, being 2-3 times more effective than GHRP-6 in stimulating GH release. Originally developed as a diagnostic agent for growth hormone deficiency, it works by mimicking ghrelin and binding to the GHS-R1a receptor.

GHRP-2 acts as a synthetic agonist of ghrelin, binding to the growth hormone secretagogue receptor (GHS-R1a) in the hypothalamus and pituitary. This stimulates cAMP production and promotes pulsatile release of endogenous growth hormone without suppressing natural feedback loops. It works synergistically with GHRH to amplify GH secretion beyond what either peptide achieves alone.

Molecular Data

D

Position 1

Alanine

Position 2

Position 3

2Nal

Position 4

Position 5

Tryptophan

Position 6

Position 7

Phenylalanine

Position 8

Lysine

Position 9

NH2

Position 10

Research Indications

Used as a diagnostic agent in Japan for assessing growth hormone deficiency in clinical settings.

Stimulates endogenous growth hormone release through ghrelin receptor activation.

Indirectly increases IGF-1 levels through enhanced GH secretion.

Enhanced muscle protein synthesis through elevated growth hormone and IGF-1 levels.

Improved lipolysis and body composition through GH-mediated fat oxidation.

Faster recovery from exercise and improved sleep quality.

Myoprotective effects in muscle atrophy models through GHS-R1a stimulation.

Cytoprotective effects observed in cardiac tissue research.

Dosing Protocols

Subcutaneous injection is the primary administration route. Best administered on an empty stomach for optimal GH release. Multiple daily doses recommended to maintain elevated GH levels.

GH optimization

100-150 mcg

2-3x daily

SubQ

Enhanced results

200-300 mcg

With GHRH (synergy)

100 mcg each

SubQ (combined)

Pre-sleep protocol

100-200 mcg

Before bed

Reconstitution Instructions

Bacteriostatic water (BAC)

Insulin syringes (0.5-1 mL)

Alcohol swabs

Peptide vial

Sterile work surface

1 Clean work area and hands thoroughly

2 Calculate required BAC water volume

3 Draw BAC water into syringe

4 Inject slowly down vial side (not directly onto powder)

5 Gently swirl until dissolved (never shake)

6 Store in refrigerator, use within 28 days

Interactions

What to Expect

Side Effects & Safety

Common Side Effects

Increased appetite (less than GHRP-6)

Mild water retention

Tingling or numbness in extremities

Tiredness or lethargy after injection

Mild headache

Stop Signs - Discontinue if:

Severe or persistent headaches

Unusual swelling in hands or feet

Signs of carpal tunnel syndrome

Allergic reactions

Contraindications

Active cancer or history of cancer

Pregnancy or breastfeeding

Pituitary disorders

Diabetic retinopathy

WADA prohibited for competitive athletes

Quality Checklist

Good Signs

White to off-white lyophilized powder

Clear solution after reconstitution

Intact vacuum seal on vial

Warning Signs

Slight clumping that dissolves easily

Bad Signs

Discolored or yellow powder

Cloudy solution after reconstitution

Particles or precipitates in solution

Frequently Asked Questions

Is GHRP-2 stronger than GHRP-6 for stimulating growth hormone?

Yes, GHRP-2 is 2-3 times more potent than GHRP-6 at stimulating GH release. However, GHRP-2 causes less appetite stimulation than GHRP-6, making it more tolerable for those sensitive to hunger effects. The trade-off is strength versus side effects—GHRP-2 is more powerful with fewer appetite issues.

How much should I dose GHRP-2 with an empty stomach requirement?

Standard GHRP-2 dosing is 100-300mcg, 2-3 times daily on a completely empty stomach (2+ hours after eating). Wait 30 minutes after injection before consuming food to optimize GH release. Best timing is morning upon waking, post-workout, and bedtime when natural GH is already elevated.

Will GHRP-2 cause elevated cortisol like some sources suggest?

At recommended doses (100-300mcg), GHRP-2 rarely elevates cortisol significantly. However, very high doses (>300mcg) or frequent dosing can increase cortisol. Most side effects are manageable water retention and appetite, with cortisol elevation primarily a concern with dose escalation beyond therapeutic ranges.

Can I use GHRP-2 if I'm diabetic or glucose-sensitive?

GHRP-2 can modestly affect glucose metabolism through GH's insulin-antagonistic effects. Diabetic users require careful monitoring and possible insulin adjustment. For glucose-sensitive individuals, monitor blood sugar before, during, and after use. Medical supervision is recommended, particularly with insulin-dependent diabetes.

References

GHRP-2 infusion increased food intake by 35.9% compared to saline, demonstrating ghrelin-like orexigenic effects.

GHRPs including GHRP-2 demonstrated significant cytoprotective effects in cardiac and extracardiac tissues.

Chronic GHRP-2 administration increased average daily gain by 22.35% and feed efficiency by 20.64%.

Related Peptides

Both are GHRPs; can be alternated but typically not stacked together.

Similar mechanism; GHRP-2 is more potent with less appetite stimulation.

No known negative interactions; different mechanisms.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

comparison

What's the dose range for cognitive enhancement versus being too much?

The cognitive 'sweet spot' is 0.5-2 mg/kg body weight (roughly 35-140 mg for a 70 kg person). Doses above 2 mg/kg often shift from antioxidant to pro-oxidant effects, becoming counterproduc…

Source: peptide-db.com
comparison

BPC-157 vs TB-500: Mechanisms, Dosing & the Wolverine Stack

How BPC-157 and TB-500 compare for healing: mechanism differences, dosing protocols, clinical evidence, and when to combine both in the Wolverine Stack.

Source: peptide-db.com
comparison

What's the ideal 5/5 vs 10/3 ratio for Tesa/IPA and when to use each?

5/5 (equal parts) provides balanced GH stimulation suitable for general recovery. The 10/3 (higher tesamorelin) variant emphasizes visceral fat loss and metabolic effects. Choose 5/5 for at…

Source: peptide-db.com
Research context

Read sources and limitations before applying a claim.

Community Research

Join others researching Crystagen — share findings, ask questions, and learn from real experiences Crystagen is a Khavinson bioregulator tripeptide (EDP) identified in thymalin with selective action on thymus tissues. Developed at Russia's St. Petersburg Institute of Bioregulation and Gerontology, it enhances immune function by stimulating normal lymphocyte proliferation while inhibiting tumor cell growth. Research shows effectiveness in normalizing immunity in 82% of elderly patients (vs 56% control) and reducing respiratory infections in athletes by doubling HSP gene expression. Crystagen works through epigenetic regulation by influencing gene expression and protein synthesis in immune cells. It regulates the synthesis of heat-shock proteins, cytokines, and affects cell differentiation, proliferation, and apoptosis. The EDP peptide enhances spontaneous proliferative activity of normal lymphocytes while inhibiting proliferation of tumor cells (K-562 erythromyelosis). It activates B-cell immune system and thymic epithelial cells (VTEC2.H/S).

Source: peptide-db.com ↗

Research Indications

FDA-approved indication. Nandrolone decanoate stimulates erythropoietin production and directly enhances erythropoiesis, increasing red blood cell mass in patients with chronic kidney disease-associated anemia. Used particularly in patients who respond poorly to erythropoiesis-stimulating agents. Historical use in aplastic anemia to stimulate red blood cell, white blood cell, and platelet production. Largely superseded by modern therapies but still considered in resource-limited settings. Nandrolone increases collagen synthesis (type I and III), synovial fluid production, and overall connective tissue integrity. Widely reported to reduce joint pain and improve function in individuals with degenerative joint conditions or training-related joint stress. The mechanism involves direct stimulation of fibroblast activity and increased procollagen mRNA expression. Nandrolone has been studied for the treatment and prevention of osteoporosis, particularly in postmenopausal women and hypogonadal men. It increases bone mineral density through direct osteoblast stimulation and suppression of osteoclast activity. Used in HIV/AIDS-associated wasting, cancer cachexia, and chronic illness-related sarcopenia to preserve and restore lean body mass. Demonstrated significant improvements in lean mass, strength, and functional capacity in clinical trials. Dose-dependent increases in lean body mass and muscle cross-sectional area. At therapeutic and supraphysiological doses, nandrolone promotes substantial gains in skeletal muscle with less water retention than equianabolic doses of testosterone. Increases in maximal strength across compound movements, driven by enhanced protein synthesis, nitrogen retention, and glycogen storage. Effects are dose-dependent and most pronounced when combined with resistance training. Nandrolone has been used to accelerate recovery from major surgery, severe burns, and debilitating injuries by promoting positive nitrogen balance, collagen deposition, and lean tissue preservation during catabolic states. Preclinical evidence suggests nandrolone may enhance tendon healing by increasing collagen fiber organization and cross-linking. Clinical applications for tendon repair remain investigational but are supported by its known collagen-stimulating properties.

Source: peptide-db.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

Dosage reference

Is survodutide's 6-day half-life long enough for once-weekly dosing?

Yes, the ~6-day half-life allows effective once-weekly dosing because peak levels remain therapeutic throughout the week. This contrasts with semaglutide (7-day half-life) - survodutide's slightly shorter half-life still covers the weekly interval adequately.

Source: peptide-db.com ↗
Side effects

Common Side Effects

Morning drowsiness or grogginess (more common at the 6 mg dose; uncommon at 3 mg) Dry mouth (mild at ultra-low doses, much less than at antidepressant doses) Nausea Upper respiratory tract infection (observed in clinical trials at rates similar to placebo)

Source: peptide-db.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →